search
Back to results

Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction

Primary Purpose

Myocardial Infarction, Inflammation, Endothelial Dysfunction

Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Simvastatin
Sponsored by
Brasilia Heart Study Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Myocardial Infarction focused on measuring myocardial infarction, inflammation, endothelial dysfunction

Eligibility Criteria

45 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Less than 24 hours after the onset of MI symptoms
  • ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
  • Myocardial necrosis, as evidenced by increased CK-MB and troponin levels

Exclusion Criteria:

  • Use of statins for at least 6 months prior the myocardial infarction

Sites / Locations

  • Hospital de Base do Distrito Federal

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

Experimental

Experimental

Arm Label

No lipid-lowering

Simvastatin 20 mg

Simvastatin 40 mg

Simvastatin 80 mg

Arm Description

No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment

Simvastatin 20 mg/day for 30 days, till the endothelial function assessment

Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment

Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment

Outcomes

Primary Outcome Measures

Elevation of plasma C reactive protein
Changes in CRP levels between the first and fifth day after myocardial infarction

Secondary Outcome Measures

Brachial Artery Endothelial function

Full Information

First Posted
May 19, 2009
Last Updated
June 21, 2011
Sponsor
Brasilia Heart Study Group
search

1. Study Identification

Unique Protocol Identification Number
NCT00906451
Brief Title
Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction
Official Title
Phase 4 Study of the Effect of Simvastatin Treatment on Inflammatory Response and Endothelial Function After Myocardial Infarction
Study Type
Interventional

2. Study Status

Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
May 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Brasilia Heart Study Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
During myocardial infarction, inflammatory response may negatively influence ventricle wall remodeling as well as endothelium-dependent vasomotor function in the coronary and systemic arterial systems. Statins have been consistently proved to attenuate inflammation and improve endothelial function. In this study, we tested the effect of different doses of statin on inflammatory response and endothelium-dependent vasodilation.
Detailed Description
During acute coronary syndromes (ACS), the generation of inflammatory mediators negatively influences arterial wall remodeling and the endothelium-dependent vasomotor function in the coronary and systemic arterial systems. The intensity of this inflammatory upregulation is strongly related to the incidence of recurrent coronary events. High dose potent statins can rapidly reduce plasma levels of cholesterol-rich lipoproteins and inflammatory activity in subjects during ACS. By inference, it is plausible to hypothesize that these effects during the acute phase of myocardial infarction may influence the post-discharge endothelial dysfunction. So far, data is unavailable to verify this assumption or to define the potency required for such statin anti-inflammatory effect in myocardial infarction patients. The present study aim to investigate the role of statin dose on the time-course of the inflammatory response during the acute phase of myocardial infarction and its late effect on endothelium-dependent arterial dilation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction, Inflammation, Endothelial Dysfunction
Keywords
myocardial infarction, inflammation, endothelial dysfunction

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
58 (Actual)

8. Arms, Groups, and Interventions

Arm Title
No lipid-lowering
Arm Type
No Intervention
Arm Description
No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
Arm Title
Simvastatin 20 mg
Arm Type
Experimental
Arm Description
Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
Arm Title
Simvastatin 40 mg
Arm Type
Experimental
Arm Description
Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
Arm Title
Simvastatin 80 mg
Arm Type
Experimental
Arm Description
Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
Intervention Type
Drug
Intervention Name(s)
Simvastatin
Intervention Description
Simvastatin
Primary Outcome Measure Information:
Title
Elevation of plasma C reactive protein
Description
Changes in CRP levels between the first and fifth day after myocardial infarction
Time Frame
Five days
Secondary Outcome Measure Information:
Title
Brachial Artery Endothelial function
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Less than 24 hours after the onset of MI symptoms ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads Myocardial necrosis, as evidenced by increased CK-MB and troponin levels Exclusion Criteria: Use of statins for at least 6 months prior the myocardial infarction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrei C Sposito, MD, PhD
Organizational Affiliation
University of Brasilia Medical School
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital de Base do Distrito Federal
City
Brasilia
State/Province
DF
ZIP/Postal Code
70000000
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
21372302
Citation
Sposito AC, Santos SN, de Faria EC, Abdalla DS, da Silva LP, Soares AA, Japiassu AV, Quinaglia e Silva JC, Ramires JA, Coelho OR. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1240-6. doi: 10.1161/ATVBAHA.110.218685. Epub 2011 Mar 3.
Results Reference
result

Learn more about this trial

Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction

We'll reach out to this number within 24 hrs